#Cipla #EliLilly #Yurpeak #Tirzepatide #DiabetesCare #ObesityManagement #Endocrinology #InternalMedicine #HealthcareProfessionals #PharmaNews #MedicalInnovation #CaringForLife #PatientCare #PharmaLeadership #HealthcareIndia Cipla has the rights to distribute and promote Yurpeak, a prescription based the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, indicated as an adjunct to diet and exercise for the treatment of type 2 diabetes and chronic weight management in adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related comorbidity
People who are unable to adequately absorb vitamin B-12 from their diet, such as those with certain medical conditions or those who follow a strict vegan diet, may benefit from this vitamin supplement being part of their semaglutide treatment
BPC 157 at Cima Health in Palm Beach Gardens Here at Cima Health, we are always on the forefront of new treatments for our patients to help you achieve whole-body wellness
Why Genetic Factors May Influence Your Response The PlexusDx Precision Peptide Genetic Test analyzes FTO (rs9939609), and MC4R (rs17782313) variants that relate to GLP-1 and related signaling pathways
For more details, see Ozempics prescribing information